A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC).

Trial Profile

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC).

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Fingolimod (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EPOC
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2016 Results (pooled subgroup analysis of this and other trial, n = 1420), assessing first-dose effects of fingolimod on cardiac outcomes in patients taking SSRIs presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 30 May 2013 Primary endpoint 'Significant difference between fingolimod and interferon beta or glatiramer acetate in Treatment-Satisfaction-Questionnaire-for-Medication score at 6 months' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top